Contrast injection during coronary angiography may lead to transient electrocardiographic (ECG) changes. The mechanism for such changes is not fully understood but may relate to the effect of contrast on cardiac membrane potentials, transient hypoxia and stimulation of endothelial pathways. Moreover, the relationship between ECG changes during angiography with sex is unclear and we aimed to explore this further.
Introduction:
Contrast injection during coronary angiography may lead to transient electrocardiographic (ECG) changes. The mechanism for such changes is not fully understood but may relate to the effect of contrast on cardiac membrane potentials, transient hypoxia and stimulation of endothelial pathways. Moreover, the relationship between ECG changes during angiography with sex is unclear and we aimed to explore this further.
Method: Patients presenting for coronary angiography were recruited. Exclusion criteria included history of cardiac bypass surgery, paced rhythm and staged coronary intervention. The right and left coronary artery (RCA & LCA) were infused with 5mls of contrast (Omnipaque) and ECG tracings were recorded. Maximal heart rate, ECG interval (PR, QRS and QT), ST segment and amplitude (R and T) during contrast injection were compared from baseline.
Results: 50 patients were recruited (females = 25), with half of the patients presenting with acute coronary syndrome. Baseline characteristics were similar between both sexes. In females, RCA angiography lead to greater R wave amplitude [1.76 (1.28) vs 1.04 (0.85) mm, p = 0.02] and total amplitude (summation of T and R wave) [2.97 (1.70) vs 1.93 (1.38), p = 0.02] when compared to males. J point height with RCA infusion was numerically higher in females [0.31 (0.17) vs 0.22 (0.17) mm, p = 0.07]. LCA angiography lead to greater QRS interval change in females [32(27.6) Aims: The use of extracorporeal membrane oxygenation (ECMO) in refractory cardiac arrest (ECPR) has increased exponentially. ECPR is a resource intensive service and its cost effectiveness has yet to be demonstrated. We sought to complete a cost analysis with modelling of cost effectiveness and quality of life outcomes.
Methods: Using data on all Extracorporeal Cardiopulmonary Resuscitation (ECPR) patients at two ECMO centres in Sydney, Australia; we completed a costing analysis of ECPR patients. A Markov model of cost, quality of life and survival outcomes was developed to examine cost per QALY estimates and incremental cost effectiveness ratios (ICERs). Probabilistic sensitivity analysis (PSA) was completed to assess the probability of cost effectiveness for base case and variations.
Results: Sixty-two ECPR patients were analysed; mean age of 51.9 ± 13.6 years, 38 (61%) were in hospital cardiac arrests (IHCA). Twenty-five patients (40%) survived to hospital discharge; all with a Cerebral Performance Category (CPC) of 1 or 2. The mean cost per ECPR patient was AUD 75,165 (D 50,535; ± AUD 75,737). Over 10 years ECPR was estimated to add a mean gain of 3.0 Quality Adjusted Life Years (QALYs) per patient with an incremental cost effectiveness ratio (ICER) of AUD 25,212 (D 16,890) per QALY, increasing to 4.0 QALYs and an ICER of AUD 18,829 (D 12,614) over a 15-year survival scenario. Mean cost per QALY did not differ significantly by OHCA or IHCA.
Conclusion: ECMO support for refractory cardiac arrests is cost effective and compares favourably to accepted cost effectiveness thresholds.
